Will - Pharma
ActiveFinancials · financial year 2025, full format
Annual accounts 2025 filed on 06-07-2026 at the NBB all 48 filings
Turnover
€17.8m▲ 9.5%
2024 · €16.3m
EBIT margin
3.3%▼ 0.1pp
2024 · 3.4%
Net result
€358,166▲ 15.4%
2024 · €310,424
Working capital
€3.8m▲ 16.9%
2024 · €3.3m
In the rankings
#1 oldest company in Walloon Brabant, Pharmaceuticals sector#7 company by equity in Wavre, Manufacturing sector#8 company by total assets in Walloon Brabant, Pharmaceuticals sector
Multi-year overview
2018 to 2025, 8 financial yearsTurnover
€17.8m
▲ 9.5%
2025
20182025
Operating result
€589,926
▲ 5.6%
2025
20182025
Net result
€358,166
▲ 15.4%
2025
middle half of the sector
20182025
EBIT margin
3.3%
▼ 0.1pp
2025
20182025
Equity
€4.7m
▲ 8.3%
2025
middle half of the sector
20182025
Total assets
€9.7m
▲ 8.0%
2025
middle half of the sector
20182025
Debt
€5.0m
▲ 8.1%
2025
20182025
Working capital
€3.8m
▲ 16.9%
2025
middle half of the sector
20182025
Solvency
47.9%
▲ 0.1pp
2025
middle half of the sector
20182025
Current ratio
1.79
▲ 0.06
2025
middle half of the sector
20182025
Return on assets (ROA)
3.7%
▲ 0.2pp
2025
middle half of the sector
20182025
Staff (FTE)
27.1
▲ 1.5%
2025
middle half of the sector
20182025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Turnover€50.9m-€63.5m▲ 24.8%€72.2m▲ 13.8%€33.7m▼ 53.3%€15.9m▼ 52.9%€15.7m▼ 0.9%€16.3m▲ 3.4%€17.8m▲ 9.5%
Operating result€0.5m--€1.1m€1.1m€3.6m▲ 230%€0.5m▼ 85.2%€0.6m▲ 9.3%€0.6m▼ 4.2%€0.6m▲ 5.6%
Net result€0.3m--€1.2m€1.0mwithin the sector's middle half€3.4mabove the sector's middle half▲ 251%€0.3mwithin the sector's middle half▼ 92.2%€0.3mwithin the sector's middle half▲ 12.5%€0.3mwithin the sector's middle half▲ 3.6%€0.4mwithin the sector's middle half▲ 15.4%
EBIT margin1.0%--1.7%▼ 2.7pp1.5%▲ 3.3pp10.7%▲ 9.2pp3.4%▼ 7.3pp3.7%▲ 0.3pp3.4%▼ 0.3pp3.3%▼ 0.1pp
Equity€5.2m-€4.1m▼ 22.4%€5.0mwithin the sector's middle half▲ 23.9%€8.4mwithin the sector's middle half▲ 67.6%€8.7mwithin the sector's middle half▲ 3.2%€4.0mwithin the sector's middle half▼ 54.1%€4.3mwithin the sector's middle half▲ 7.8%€4.7mwithin the sector's middle half▲ 8.3%
Total assets€16.3m-€17.9m▲ 9.5%€20.1mwithin the sector's middle half▲ 12.4%€16.5mwithin the sector's middle half▼ 17.9%€17.9mwithin the sector's middle half▲ 8.8%€9.5mwithin the sector's middle half▼ 47.2%€9.0mwithin the sector's middle half▼ 4.9%€9.7mwithin the sector's middle half▲ 8.0%
Debt€10.9m-€13.6m▲ 25.0%€14.8m▲ 8.6%€7.9m▼ 46.5%€9.2m▲ 15.5%€5.4m▼ 41.3%€4.7m▼ 13.5%€5.0m▲ 8.1%
Working capital€1.8m-€0.4m▼ 75.6%€1.6mwithin the sector's middle half▲ 269%€6.8mwithin the sector's middle half▲ 324%€7.3mwithin the sector's middle half▲ 7.3%€2.9mwithin the sector's middle half▼ 60.5%€3.3mwithin the sector's middle half▲ 13.4%€3.8mwithin the sector's middle half▲ 16.9%
Solvency32.1%-22.7%▼ 9.3pp25.0%within the sector's middle half▲ 2.3pp51.1%within the sector's middle half▲ 26.1pp48.5%within the sector's middle half▼ 2.7pp42.2%within the sector's middle half▼ 6.3pp47.8%within the sector's middle half▲ 5.6pp47.9%within the sector's middle half▲ 0.1pp
Current ratio1.17-1.03▼ 0.131.11within the sector's middle half▲ 0.081.86within the sector's middle half▲ 0.751.80within the sector's middle half▼ 0.061.55within the sector's middle half▼ 0.251.73within the sector's middle half▲ 0.181.79within the sector's middle half▲ 0.06
Return on assets (ROA)1.7%--6.6%▼ 8.3pp4.8%within the sector's middle half▲ 11.4pp20.6%above the sector's middle half▲ 15.8pp1.5%within the sector's middle half▼ 19.1pp3.2%within the sector's middle half▲ 1.7pp3.4%within the sector's middle half▲ 0.3pp3.7%within the sector's middle half▲ 0.2pp
Staff (FTE)39-37▼ 5.1%38.9within the sector's middle half▲ 5.1%27.9within the sector's middle half▼ 28.3%25.7within the sector's middle half▼ 7.9%24.4within the sector's middle half▼ 5.1%26.7within the sector's middle half▲ 9.4%27.1within the sector's middle half▲ 1.5%
above
within
below
The sector band is the middle half of the companies in Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 6% higher than in 2024. It is a recovery after the fall in 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €9.7m
Fixed assets
€1.1m ▼ 16.0%
Current assets
€8.7m ▲ 11.9%
Equity and liabilities €9.7m
Equity
€4.7m ▲ 8.3%
Provisions
€37,111 ▼ 28.8%
Debt
€5.0m ▲ 8.1%
Debt's share of the balance-sheet total rises from 51.6% to 51.7%. Equity and debt are higher.
Key figures and ratios
EBITDA
€929,417▲
2024 · €893,486
Cash flow
€697,656▲
2024 · €645,034
Quick ratio
0.77▲
2024 · 0.57
Debt to equity
1.08▼
2024 · 1.08
ROE
7.7%▲
2024 · 7.2%
Interest coverage
22.39▼
2024 · 22.50
Debt ≤ 1 year
€4.9m▲
2024 · €4.5m
Income taxes
€161,860▼
2024 · €166,106
Customer credit
31 days▼
2024 · 33 days
Supplier credit
160 days▼
2024 · 168 days
Staff costs
€2.8m▲
2024 · €2.6m
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Staff
| Item | 31-12-2021 | 31-12-2022 | 31-12-2023 | 31-12-2024 | 31-12-2025 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 28 | 26 | 25 | 27 | 29 |
| full-time | 25 | 23 | 23 | 22 | 24 |
| part-time | 3 | 3 | 2 | 5 | 5 |
| in full-time equivalents | 27.3 | 25.3 | 24.7 | 26.3 | 28.3 |
| Average over the year, in full-time equivalents | 27.9 | 25.7 | 24.4 | 26.7 | 27.1 |
| On a permanent contract | 27 | 26 | 25 | 27 | 29 |
| Joined | 9 | 5 | 10 | 9 | 8 |
| Left | 20 | 7 | 11 | 7 | 6 |
| Agency workers, average number | 1.5 | 0.3 | 1.6 | 0.4 | 0.3 |
| Training hours | 175 | 161 | 161 | 161 | 161 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Overdue debts
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Overdue social security (RSZ) debts | - | €0 | - | - | - |
Source: notes to the 2021 to 2025 annual accounts (statement of debts)
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €263,668 | €51,682 | €220,784 | €240,033 | €119,352 |
| Intangible fixed assets | €26,979 | - | - | - | €40,506 |
| Depreciation and write-downs of the year | €340,347 | €342,423 | €321,158 | €334,610 | €339,490 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Auditor
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Fee for the audit | €12,750 | €15,500 | €16,400 | €16,680 | €18,000 |
Source: notes to the 2021 to 2025 annual accounts (relations with the auditor)
Public contracts
4 awards · 2026
Raamovereenkomst voor het leveren van geneesmiddelen tegen pijn, koorts en osteo-articulaire aandoeningen: Calcium en Vitamine D: kauwtablet
Raamovereenkomst voor het leveren van geneesmiddelen tegen pijn, koorts en osteo-articulaire aandoeningen: Calcium en vitamine D: zakje/bruistablet
Raamovereenkomst voor het leveren van hemostatica: Geoxideerd geregenereerd cellulose
Raamovereenkomst voor het leveren van hemostatica: Gelatine: farmaceutisch of varken
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. The values are as the buyer published them. For a framework agreement, the value is a ceiling.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | - | €37.3m | €16.1m | €16.0m | €16.5m | €18.1m | ▲ 9.9% |
| Turnover70 | €50.9m | €63.5m | €72.2m | €33.7m | €15.9m | €15.7m | €16.3m | €17.8m | ▲ 9.5% |
| Other operating income74 | - | - | - | €0.5m | €0.2m | €0.3m | €0.2m | €0.3m | ▲ 37.8% |
| Non-recurring operating income76A | - | - | - | €3.1m | - | - | - | - | - |
| Operating charges60/66A | - | - | - | €33.7m | €15.5m | €15.4m | €15.9m | €17.5m | ▲ 10.0% |
| Goods for resale, raw materials and consumables60 | - | - | - | €24.4m | €6.6m | €5.6m | €6.1m | €6.9m | ▲ 12.3% |
| Purchases600/8 | - | - | - | €25.0m | €6.3m | €6.6m | €7.0m | €7.0m | = |
| Change in stocks: decrease (increase)609 | - | - | - | -€0.6m | €0.3m | -€1.0m | -€0.9m | -€0.1m | ▲ 88.3% |
| Services and other goods61 | - | - | - | €6.1m | €6.0m | €6.9m | €6.7m | €7.1m | ▲ 5.0% |
| Remuneration, social security and pensions62 | - | - | - | €2.6m | €2.5m | €2.5m | €2.6m | €2.8m | ▲ 9.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.2m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | ▲ 1.5% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €0.2m | €0.08m | €0.1m | €0.06m | €0.3m | ▲ 432% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | -€0.08m | -€0.02m | €0.03m | -€0.03m | - | - |
| Other operating charges640/8 | - | - | - | €0.06m | €0.09m | €0.06m | €0.1m | €0.1m | ▲ 0.1% |
| Operating profit (loss)9901 | €0.5m | -€1.1m | €1.1m | €3.6m | €0.5m | €0.6m | €0.6m | €0.6m | ▲ 5.6% |
| Financial income75/76B | - | - | - | €0.007m | €0.03m | €0.03m | €0.001m | €0.01m | ▲ 12× |
| Recurring financial income75 | €0.004m | €0.001m | €0.007m | €0.007m | €0.03m | €0.03m | €0.001m | €0.01m | ▲ 12× |
| Other financial income752/9 | - | - | - | €0.007m | €0.03m | €0.03m | €0.001m | €0.01m | ▲ 12× |
| Financial charges65/66B | - | - | - | €0.07m | €0.2m | €0.2m | €0.1m | €0.1m | ▼ 7.6% |
| Recurring financial charges65 | €0.06m | €0.07m | €0.07m | €0.07m | €0.2m | €0.2m | €0.1m | €0.1m | ▼ 7.6% |
| Debt charges650 | €0.02m | €0.03m | €0.03m | €0.03m | €0.03m | €0.02m | €0.04m | €0.04m | ▲ 4.6% |
| Other financial charges652/9 | - | - | - | €0.04m | €0.1m | €0.2m | €0.06m | €0.05m | ▼ 15.2% |
| Profit (loss) for the period before taxes9903 | €0.4m | -€1.2m | €1.0m | €3.5m | €0.4m | €0.4m | €0.5m | €0.5m | ▲ 10.6% |
| Transfer from deferred taxes780 | - | - | - | €0.02m | €0.02m | €0.02m | €0.02m | €0.01m | ▼ 24.8% |
| Income taxes67/77 | €0.008m | €0.009m | €0.07m | €0.2m | €0.2m | €0.2m | €0.2m | €0.2m | ▼ 2.6% |
| Taxes670/3 | - | - | - | €0.2m | €0.2m | €0.2m | €0.2m | €0.2m | ▼ 2.6% |
| Profit (loss) for the period9904 | €0.3m | -€1.2m | €1.0m | €3.4m | €0.3m | €0.3m | €0.3m | €0.4m | ▲ 15.4% |
| Transfer from tax-exempt reserves789 | - | - | - | €0.07m | €0.07m | €0.07m | €0.06m | €0.04m | ▼ 24.8% |
| Profit (loss) for the period to be appropriated9905 | -€0.2m | -€1.2m | €1.0m | €3.5m | €0.3m | €0.4m | €0.4m | €0.4m | ▲ 8.9% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €16.3m | €17.9m | €20.1m | €16.5m | €17.9m | €9.5m | €9.0m | €9.7m | ▲ 8.0% |
| Fixed assets21/28 | €3.7m | €3.9m | €3.7m | €1.8m | €1.5m | €1.4m | €1.3m | €1.1m | ▼ 16.0% |
| Intangible fixed assets21 | €1.3m | €1.5m | €1.4m | €1.2m | €1.0m | €0.8m | €0.7m | €0.5m | ▼ 19.2% |
| Tangible fixed assets22/27 | €0.6m | €0.5m | €0.5m | €0.6m | €0.5m | €0.5m | €0.6m | €0.5m | ▼ 12.6% |
| Land and buildings22 | - | - | - | €0.4m | €0.4m | €0.4m | €0.4m | €0.3m | ▼ 11.5% |
| Plant, machinery and equipment23 | - | - | - | €0.09m | €0.07m | €0.09m | €0.2m | €0.1m | ▼ 15.7% |
| Furniture and vehicles24 | - | - | - | €0.04m | €0.03m | €0.03m | €0.04m | €0.03m | ▼ 9.9% |
| Other tangible fixed assets26 | - | - | - | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | = |
| Assets under construction and advance payments27 | - | - | - | - | €0.02m | €0.02m | €0.006m | €0.003m | ▼ 42.4% |
| Financial fixed assets28 | €1.8m | €1.8m | €1.8m | €0.003m | €0.003m | €0.003m | €0.003m | €0.003m | = |
| Affiliated companies280/1 | - | - | - | €0 | - | - | - | - | - |
| Participating interests280 | - | - | - | €0 | - | - | - | - | - |
| Other financial fixed assets284/8 | - | - | - | €0.003m | €0.003m | €0.003m | €0.003m | €0.003m | = |
| Amounts receivable and cash guarantees285/8 | - | - | - | €0.003m | €0.003m | €0.003m | €0.003m | €0.003m | = |
| Current assets29/58 | €12.6m | €14.0m | €16.4m | €14.7m | €16.4m | €8.1m | €7.8m | €8.7m | ▲ 11.9% |
| Stocks and contracts in progress3 | €1.9m | €3.3m | €3.8m | €4.1m | €3.6m | €4.5m | €5.2m | €5.0m | ▼ 5.1% |
| Stocks30/36 | - | - | - | €4.1m | €3.6m | €4.5m | €5.2m | €5.0m | ▼ 5.1% |
| Raw materials and consumables30/31 | - | - | - | €0.3m | €0.4m | €0.6m | €0.4m | €0.4m | ▲ 14.8% |
| Finished goods33 | - | - | - | €3.8m | €3.3m | €3.9m | - | - | - |
| Goods purchased for resale34 | - | - | - | - | - | - | €4.8m | €4.5m | ▼ 6.7% |
| Amounts receivable within one year40/41 | €9.1m | €8.1m | €11.0m | €9.9m | €11.0m | €1.9m | €1.8m | €2.0m | ▲ 13.6% |
| Trade receivables40 | - | - | - | €4.5m | €5.7m | €1.2m | €1.4m | €1.5m | ▲ 5.6% |
| Other amounts receivable41 | - | - | - | €5.4m | €5.3m | €0.7m | €0.3m | €0.5m | ▲ 47.0% |
| Current investments50/53 | €0.2m | €0.01m | €0.01m | €0.003m | €0.003m | €0.003m | €0.003m | €0.003m | ▼ 1.0% |
| Other investments51/53 | - | - | - | €0.003m | €0.003m | €0.003m | €0.003m | €0.003m | ▼ 1.0% |
| Cash at bank and in hand54/58 | €1.4m | €2.5m | €1.6m | €0.6m | €1.7m | €1.6m | €0.6m | €1.5m | ▲ 176% |
| Deferred charges and accrued income490/1 | - | - | - | €0.1m | €0.08m | €0.08m | €0.2m | €0.1m | ▼ 19.1% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €16.3m | €17.9m | €20.1m | €16.5m | €17.9m | €9.5m | €9.0m | €9.7m | ▲ 8.0% |
| Equity10/15 | €5.2m | €4.1m | €5.0m | €8.4m | €8.7m | €4.0m | €4.3m | €4.7m | ▲ 8.3% |
| Contributions10/11 | €3.0m | €3.0m | €3.0m | €3.0m | €3.0m | €3.0m | €3.0m | €3.0m | = |
| Capital10 | - | - | - | €3.0m | €3.0m | €3.0m | €3.0m | €3.0m | = |
| Issued capital100 | - | - | - | €3.0m | €3.0m | €3.0m | €3.0m | €3.0m | = |
| Contributions outside capital11 | - | - | - | €0.04m | €0.04m | €0.04m | €0.04m | €0.04m | = |
| Share premium1100/10 | - | - | - | €0.04m | €0.04m | €0.04m | €0.04m | €0.04m | = |
| Reserves13 | €1.3m | €1.3m | €1.3m | €1.4m | €1.3m | €0.5m | €0.5m | €0.4m | ▼ 9.4% |
| Non-distributable reserves130/1 | - | - | - | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | = |
| Legal reserve130 | - | - | - | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | = |
| Other1319 | - | - | - | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | = |
| Tax-exempt reserves132 | - | - | - | €0.3m | €0.3m | €0.2m | €0.2m | €0.1m | ▼ 28.8% |
| Distributable reserves133 | - | - | - | €0.7m | €0.7m | €0.005m | €0.005m | €0.005m | = |
| Profit (loss) carried forward14 | €0.9m | -€0.2m | €0.7m | €4.1m | €4.4m | €0.4m | €0.8m | €1.2m | ▲ 49.3% |
| Provisions and deferred taxes16 | €0.2m | €0.2m | €0.2m | €0.1m | €0.09m | €0.1m | €0.05m | €0.04m | ▼ 28.8% |
| Provisions for liabilities and charges160/5 | - | - | - | €0.02m | - | €0.03m | - | - | - |
| Other liabilities and charges164/5 | - | - | - | €0.02m | - | €0.03m | - | - | - |
| Deferred taxes168 | - | - | - | €0.1m | €0.09m | €0.07m | €0.05m | €0.04m | ▼ 28.8% |
| Amounts payable17/49 | €10.9m | €13.6m | €14.8m | €7.9m | €9.2m | €5.4m | €4.7m | €5.0m | ▲ 8.1% |
| Amounts payable within one year42/48 | €10.8m | €13.6m | €14.8m | €7.9m | €9.1m | €5.2m | €4.5m | €4.9m | ▲ 8.3% |
| Financial debts43 | - | - | - | €1.2m | €1.1m | - | - | - | - |
| Credit institutions430/8 | - | - | - | €1.2m | €1.1m | - | - | - | - |
| Trade debts44 | €9.6m | €12.6m | €13.6m | €3.8m | €4.7m | €3.6m | €2.8m | €3.0m | ▲ 6.9% |
| Suppliers440/4 | - | - | - | €3.8m | €4.7m | €3.6m | €2.8m | €3.0m | ▲ 6.9% |
| Taxes, remuneration and social security45 | - | - | - | €0.3m | €0.5m | €0.4m | €0.5m | €0.7m | ▲ 29.2% |
| Taxes450/3 | - | - | - | €0.04m | €0.1m | €0.07m | €0.1m | €0.09m | ▼ 5.9% |
| Remuneration and social security454/9 | - | - | - | €0.3m | €0.3m | €0.3m | €0.4m | €0.6m | ▲ 37.9% |
| Other amounts payable47/48 | - | - | - | €2.6m | €2.8m | €1.2m | €1.2m | €1.2m | ▲ 2.6% |
| Accrued charges and deferred income492/3 | - | - | - | €0.04m | €0.02m | €0.2m | €0.2m | €0.2m | ▲ 4.2% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €0.3m | -€1.2m | €1.0m | €3.4m | €0.3m | €0.3m | €0.3m | €0.4m | ▲ 15.4% |
| + Depreciation and write-downs630 | €0.2m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | ▲ 1.5% |
| Operating cash flow (approximation) | €0.5m | -€0.9m | €1.3m | €3.7m | €0.6m | €0.6m | €0.6m | €0.7m | ▲ 8.2% |
| Investment in fixed assets (approximation) | - | -€0.4m | -€0.1m | €1.5m | -€0.05m | -€0.2m | -€0.2m | -€0.1m | ▲ 37.4% |
| Change in cash | - | €1.1m | -€0.9m | -€0.9m | €1.1m | -€0.04m | -€1.1m | €1.0m | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 14,766 companies had the same profile as Will - Pharma has now. Two years later, 96.2% were still going and 0.2% had gone bankrupt.
- Small
- 20 years or older
- solvency 30% or more
- a profit under 5% of the balance sheet
96.2%
was still going
3.5%
stopped otherwise
0.2%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of Will - Pharma itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 14,766 companies, not a prediction for Will - Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 48 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | full format | 06-07-2026 | 2026-00269889 | |
| 31-12-2024 | full format | 27-06-2025 | 2025-00192221 | |
| 31-12-2023 | full format | 17-07-2024 | 2024-00254991 | |
| 31-12-2022 | full format | 25-07-2023 | 2023-00267351 | |
| 31-12-2021 | full format | 25-07-2022 | 2022-20217344 | |
| 31-12-2020 | full format | 26-07-2021 | 2021-40300414 | |
| 31-12-2019 | full format | 09-09-2020 | 2020-52400070 | |
| 31-12-2018 | full format | 23-07-2019 | 2019-37400446 | |
| 31-12-2017 | full format | 30-07-2018 | 2018-41400295 | |
| 31-12-2016 | full format | 30-06-2017 | 2017-26800126 |